Press Releases
Date Title and Summary View
Apr 25, 2015 - Two late breaker presentations detail previously announced 100% SVR12 in Phase 2 trial evaluating 6- or 8-weeks of treatment with ACH-3102 and sofosbuvir in genotype 1 HCV patients and Phase 1 proof-of-concept results with ACH-3422 -- Clinical virology presentation continues to support improved barrier to resistance with ACH-3102 - VIENNA, Au...
Apr 8, 2015 NEW HAVEN, Conn., April 8, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it will present three posters, including two late breaker abstracts, at the 50th Annual Meeting of the European Association for the Study of the Liver (EASL) during The International Liver Congress 2015. Poster presentations will i...
Mar 5, 2015 NEW HAVEN, Conn., March 5, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and twelve months ended December 31, 2014. For the three months ended December 31, 2014, the Company reported a net loss of $21.6 million, compared to a net loss of $13.4 million in the three months en...
Feb 18, 2015 NEW HAVEN, Conn., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the closing of its previously announced public offering of common stock. Achillion sold 13,800,000 shares of its common stock in the offering at a price to the public of $10.25 per share, including the exercise in full by the underwrite...
Feb 11, 2015 NEW HAVEN, Conn., Feb. 11, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $10.25 per share. All of the shares in the offering will be sold by Achillion. The net proceeds to Achillion from the sa...
Feb 10, 2015 NEW HAVEN, Conn., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that it has commenced an underwritten public offering of 10,000,000 shares of its common stock. In connection with this offering, Achillion plans to grant the underwriters a 30-day option to purchase additional shares of its common stoc...
Feb 9, 2015 - Achillion achieves 100% SVR12 in six-week regimen with combination of ACH-3102 and sofosbuvir for treatment-naïve genotype 1 HCV -- Achillion to initiate 4-week treatment regimens based on the strength of ACH-3102 antiviral data - NEW HAVEN, Conn., Feb. 9, 2015 (GLOBE NEWSWIRE) --Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announ...
Feb 6, 2015 NEW HAVEN, Conn., Feb. 6, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences: Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 8:55 a....
Dec 22, 2014 - A six-week dual NS5A - Nuc regimen of ACH-3102 and sofosbuvir was safe and well-tolerated with 100 percent SVR4 for treatment-naïve genotype 1 HCV ("Proxy Study")- ACH-3422 proof-of-concept trial showed it was safe and well-tolerated at doses of 50 mg-700 mg once daily achieving 4.8 log10 reduction with 700 mg dose after 14 days -- Conferenc...
Nov 25, 2014 NEW HAVEN, Conn., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present a corporate overview at two upcoming investor conferences: 2014 Deutsche Bank BioFEST on Monday, December 1, 2014 at 9:15 a.m. ET at the Four Seasons Hotel in Boston, MA; and ...
1
... NextLast
Add to Briefcase = add release to Briefcase

built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue